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The association between skin auto-
fluorescence of palmoplantar sites 
and microvascular complications in 
Asian patients with type 2 diabetes 
mellitus
Jong Jin Kim1, Bosu Jeong1, Yongin Cho2, Mi-hyang Kwon2, Yong-ho Lee  2,3,4, Uk Kang1 & 
Eun Seok Kang  2,3,4
Skin auto-fluorescence (SAF) has generated broad interest about the prospects for non-invasive 
advanced glycation end product assessment and its direct interplay with the development of 
microvascular complications, but clinical application of the existing SAF measuring of non-palmoplantar 
sites in non-Caucasian subjects with dark skin type is still controversial. Here, we tested the diabetic 
complication screening performance of a novel SAF measuring system in Asian type 2 diabetes mellitus 
(T2DM) subjects. A total of 166 Korean patients with T2DM were enrolled in this study and palmoplantar 
SAF was measured by a newly developed transmission-geometry noninvasive optical system. We 
found that transmitted SAF values of palmoplantar sites, 1st dorsal interossei muscles of the hand, in 
a complication group were significantly higher than in a non-complication group while no differences 
were observed between the two groups in reflected SAF of non-palmoplantar sites. The transmitted 
SAF values of palmoplantar sites were dramatically increased in subjects with multiple complications 
and were tightly correlated with the duration of microvascular complications. In conclusion, the SAF 
measurement in the palmoplantar sites with a non-invasive transmission-geometry optical system 
provided better microvascular complication screening performance compared to the SAF measurement 
of non-palmoplantar sites specifically in Asian T2DM subjects.
The blood glucose homeostasis is tightly regulated throughout the body and is critically important to ensure 
sufficient glucose supply for metabolic demands. In patients with diabetes mellitus, sustained defects in the 
blood-glucose regulatory system, however, induce long-standing hyperglycemic state, lead to a persistent 
non-enzymatic reaction between reducing sugar and amino groups of proteins, lipids and nucleic acids and even-
tually form irreversible advanced glycation end-products (AGEs)1,2. The hyperglycemia-induced AGE formation 
and accumulation in tissues is involved in diverse pathophysiological processes and plays a pivotal role in the 
progression of different microvascular complications including nephropathy, retinopathy and neuropathy, which 
are rapidly expanding serious health problems3–5.
Nonenzymatic collagen cross-linking occurs throughout the body as a consequence of AGE pathogenesis6. 
Multiple research groups have demonstrated that skin auto-fluorescence (SAF) mainly emanating from cumula-
tive AGE-mediated collagen cross-linking with slow-turnover is correlated to a wide variety of long-term com-
plications especially in patients with DM7–9. Unlike invasive AGE quantification in human tissue samples, the 
SAF has generated broad interest about the prospects for non-invasive AGE assessment and earlier detection 
of microvascular complications10. Despite the general consensus that SAF may be a promising biomarker for 
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the development and progression of AGE-mediated microvascular complications, several confounding factors 
should be further considered before its clinical application. SAF is conventionally measured on the volar side of 
the forearms where dark pigmentation density is relatively higher than in palmoplantar sites11–13. Among sev-
eral SAF confounding factors, dark pigmentation in non-palmoplantar areas may affect SAF measurement and 
interrupt the coupling between measured SAF and past long-term glycemic status14. Thus, extra attention even 
in Caucasian subjects should be necessary to perform SAF measurement on the volar side of the forearms with 
less dark pigmentation.
In the previous study, we reported that non-invasive SAF measurement of the palmoplantar sites, 1st dorsal 
interossei muscles of the hand with transmission-geometry provided a superior diagnostic performance of abnor-
mal glucose tolerance (AGT) in Korean subjects even compared to blood sample based AGT diagnosis or to SAF 
reflected from non-palmoplantar sites15. Here, we tested the diabetic complication screening performance of SAF 
transmitted through the 1st dorsal interossei muscles with a newly developed optical system in Korean patients 
with type 2 diabetes mellitus (T2DM).
Figure 1. Glycated Serum Protein levels and Microvascular Complications. Statistical comparison of HbA1c, 
GA and GA/HbA1c ratio between a non-complication group and a complication group. Error bars represent 
standard deviation.
Figure 2. SAF and Microvascular Complications. (a) Statistical comparison of reflected SAF values on 
the volar side of the forearms (SAF-R) between a complication group and a non-complication group. (b) 
Statistical comparison of transmitted SAF values in the 1st dorsal interossei muscles of the hand (SAF-T) 
between a complication group and a non-complication group. (c) SAF-T values with respect to the number of 
microvascular complications. (d) SAF-T utilized receiver operating characteristic curves regarding different 
microvascular complications. Error bars represent standard deviation. (Asterisks *, **, ***, and **** indicate 
p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively).
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Results
Of a total of 166 Korean patients with T2DM, the prevalence of diabetic microvascular complications was 66.2% 
(n = 110); specifically, 36.1% (n = 60), 23.5% (n = 39), and 41.6% (n = 69) of subjects had retinopathy, neuropa-
thy, and nephropathy, respectively. In the physical examination, significant differences between a complication 
group and a non-complication group were not clearly observed with respect to sex, age, body mass index, and 
systolic blood pressure and diastolic blood pressure. There were no statistical differences in HbA1c, glycated albu-
min (GA) and the ratio of GA and HbA1c (GA/HbA1c) between two groups (Fig. 1 and Table 1). On the other 
hand, complication group had significantly longer T2DM duration and had higher risks of hypertension or hyper-
lipidemia with no difference in fasting plasma glucose and glycated albumin levels (Table 1). The proportions of 
angiotensin converting inhibitors (ACEi), angiotensin receptor blocker (ARB) and statin user were higher in the 
group with complications. Patients’ characteristics are shown in Table 1.
There were no differences between a complication group and a non-complication group with respect to SAF 
values measured on the volar side of the forearm (SAF-R, Fig. 2a). On the other hand, measured SAF values 
of the 1st dorsal interossei muscles of the hand (SAF-T) in a complication group were found to be significantly 
higher than in a non-complication group (6.41 ± 2.50 A.U. vs. 5.10 ± 1.68 A.U., P = 0.0005, Fig. 2b). Intriguingly, 
the SAF-T was significantly increased in subjects with multiple complications; one complication (n = 62), 
5.23 ± 2.40 A.U.; two complications (n = 38), 6.40 ± 2.42 A.U.; three complications (n = 10), 7.78 ± 2.69 A.U., 
P < 0.000 1 (Fig. 2c).
Subjects with DM 
complication (n = 110)
Subjects without DM 
complication (n = 56) P value
Age, years 60.9 ± 11.5 59.3 ± 10.7 0.368
Sex, male 72 (65.5) 39 (69.6) 0.588
Body mass index, kg/m2 25.4 ± 4.2 25.5 ± 4.1 0.914
Waist circumference, cm 89.9 ± 9.6 89.1 ± 9.7 0.610
SBP, mmHg 123.7 ± 15.1 121.2 ± 12.3 0.287
DBP, mmHg 71.4 ± 9.3 73.9 ± 10.8 0.121
DM duration, years 12.7 ± 9.1 8.6 ± 6.4 <0.001
HbA1c, % 7.4 ± 1.4 7.1 ± 1.2 0.218
HbA1c, mmol/mol 57 ± 16 54 ± 13 0.218
Glycated Albumin, % 19.3 ± 5.7 17.7 ± 5.0 0.107
GA/HbA1c (AU) 2.4 ± 0.9 2.3 ± 0.8 0.103
FPG, mg/dL 134.5 ± 44.2 127.2 ± 32.0 0.224
Total cholesterol, mg/dL 158.8 ± 33.9 160.5 ± 34.8 0.768
HDL-cholesterol, mg/dL 43.7 ± 10.7 45.5 ± 10.9 0.144
Triglyceride, mg/dL 148.7 ± 79.3 132.9 ± 57.1 0.304
LDL-cholesterol, mg/dL 85.5 ± 27.4 88.4 ± 29.3 0.517
UACR (mg/g) 477.1 ± 1430.0 10.5 ± 9.9 0.001
eGFR (ml/min/1.73 m2) 77.0 ± 30.8 88.1 ± 19.1 0.005
SAF-R (AU) 2.8 ± 1.1 3.0 ± 1.2 0.306
SAF-T (AU) 6.4 ± 2.5 5.1 ± 1.7 <0.001
Hypertension 78 (70.9) 26 (46.4) 0.002
ACEIs or ARBs 71 (64.5) 19 (33.9) <0.001
CCBs 39 (35.5) 17 (30.4) 0.316
Beta-blockers 26 (23.6) 12 (21.4) 0.455
Diuretics 20 (18.2) 6 (10.7) 0.152
Hyperlipidemia 86 (78.2) 35 (62.5) 0.032
Statins 75 (68.2) 29 (51.8) 0.030
Ezetimibe 15 (13.6) 3 (5.4) 0.083
Fenofibrate 7 (6.4) 2 (3.6) 0.362
Retinopathy 60 (36.1) —
Neuropathy 39 (23.5) —
Nephropathy 69 (41.6) —
Table 1. Baseline characteristics of patients according to the complication status. Data are expressed as the 
mean ± standard deviation (SD) for continuous variables and percentage (%) for categorical variables. SBP, 
systolic blood pressure; DBP, diastolic blood pressure; AU, arbitrary unit; FPG, fasting plasma glucose; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; UACR, urine albumin-to-creatinine ratio; eGFR, 
estimated glomerular filtration rate; SAF-R, reflected skin auto-fluorescence on the volar side of the forearms; 
SAF-T, transmitted skin auto-fluorescence in the 1st interossei muscle of the hand; ACEIs, angiotensin 
converting enzyme inhibitors; ARBs, angiotensin receptor blockers and CCBs, calcium channel blockers.
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Pearson’s correlation coefficient revealed that the SAF-T values were positively correlated with the duration 
of T2DM in each subject (r = 0.2439; P = 0.0015) but independent to the prevalence of hypertension or hyper-
lipidemia and to all the other physical parameters. The correlation of the duration of T2DM with the number 
of microvascular complications in each subject was significant (r = 0.2984, P < 0.0001). In univariate logistic 
regression, microvascular diabetic complications were associated with SAF-T, DM duration, hypertension and 
hyperlipidemia. Multivariate logistic regression showed that SAF-T (odds ratio (OR), 1.31; 95% confidence inter-
val [CI], 1.08–1.56; P = 0.005) and hypertension (OR, 2.17; 95% CI, 1.04–4.52; P = 0.04) were independent risk 
factors for complications. When the purpose of a multivariable regression analysis is to explain the individual 
effects of the predictors on an outcome variable, potential multicollinearity between the variables should be fur-
ther investigated. Multicollinearity between SAF-T and diabetes duration was assessed using variation influence 
factor (VIF). VIF was 1.026 which excluded a serious problem with multicollinearity16. In addition, the area 
under curve (AUC) came out to be 0.661 which is statistically significant (P < 0.001) in that SAF-T can predict the 
diabetic microvascular complication shown by this method (Fig. 2d). An SAF-T cutoff of 4.83 A.U. produced the 
maximum Youden index, a sum of sensitivity (72.73%) and specificity (55.36%) by Receiver operating character-
istic (ROC) analysis. At the SAF-T cutoff of 4.83 A.U., sensitivity for the presence of one or more complications, 
or diabetic microvascular complication (retinopathy, neuropathy, and nephropathy) was calculated. It predicted 
one complication at a sensitivity of 61.29% with an AUC of 0.588, two complications at a sensitivity of 86.84% 
with an AUC of 0.734, and three complications at a sensitivity of 90.00% with an AUC of 0.843. The sensitivity 
and the AUC significantly increased with an increasing number of complications. Regarding diabetic microvas-
cular complications, patients with retinopathy, neuropathy, and nephropathy were identified with a sensitivity of 
71.67%, 84.62%, and 79.71%, respectively. An AUC for determining retinopathy was 0.669, neuropathy was 0.732, 
and nephropathy was 0.707, respectively. An ROC analysis revealed that the AUC for SAF had a high predictive 
ability for the presence of neuropathy among diabetic vascular complications.
Discussions
The glycated serum proteins that are predominant Amadori-type glycation products have long been considered 
as a determinant marker of the glycemic status over the previous two to four weeks17,18. Moreover, several clinical 
studies have reported that glycated serum protein levels; especially glycated serum albumin levels are tightly 
associated with the onset of vascular complications by inducing inflammatory mediators in the vascular wall6,19. 
However, it is still controversial whether a single measurement of glycated serum protein level can be an effective 
predictor of diabetic complication onset in clinical practice. In the present study, we found that there were no 
significant differences between groups with and without any developing diabetic complications with respect to 
glycated serum protein levels including HbA1c and GA levels or to HbA1c/GA ratio. Furthermore, we found 
HbA1c and GA levels were uncoupled to the duration of T2DM that has been well described as a diabetic compli-
cation co-factor. Thus, our data confirms that temporal glycated serum protein levels in patients with T2DM do 
not reflect the long-term glycemic history that correlates with the severity of diabetic complications.
Unlike short-lived glycation serum proteins, AGEs have been implicated as a long-term memory of glycemic 
status20,21. In patients with chronic hyperglycemia, AGE formation and accumulation of proteins or tissues and 
its direct interplay with multiple pathogenic processes have long been considered as a major threatening factor 
of diabetic complication onset3. Once AGE pathogenesis triggers macro- or micro-angiopathy, impaired cellular 
AGE defense system as well as enhanced oxidative stress, in turn, promote further AGE accumulation. In clini-
cal settings, the assessment of tissue AGE overload was first conducted with immunolabeling methods in tissue 
biopsy specimens including retinal blood walls or peripheral nerves22–24. Although the direct assessment of AGE 
quantification from specific target tissues advanced our knowledge on the direct link between AGE accumulation 
and the severity of diabetic complications, such invasive AGE assessment technique still hampers clinical appli-
cation because of high surgical difficulties and costs.
In the previous study, the skin biopsies were obtained from the same measurement site in which label-free 
skin fluorescence measurement was conducted and several AGEs were quantified with multimodal methods25,26. 
The study emphasized that skin fluorescence is closely associated with dermal AGE levels and the development 
of non-invasive label-free skin fluorescence measuring system enables reliable assessment of the degree of AGE 
pathogenesis throughout the body. During the last decade, multiple research groups have demonstrated that skin 
fluorescence on the volar side of the forearms is closely associated with the progression of different microvascular 
complications in patients with diabetes mellitus up to Fitzpatrick skin phototype class IV14,27,28. This tight cou-
pling is owing to temporal relationship between skin fluorescence intensity and past long-term glycemic status. 
However, elevated dermal chromophores in subjects with dark skin type can result in inaccurate skin fluorescence 
assessment and eventually lead to unreliable outcomes29.
In this study, we found that whereas SAF of the volar side of the forearm with a reflection-geometry optical 
system remained unassociated with the diabetic complications in Korean patients with T2DM, SAF measured in 
the 1st dorsal interossei muscle of the hand with a newly developed transmission-geometry optical system was 
strongly associated with the onset of progressive or sustained diabetic complications in Korean patients with 
T2DM, in which more than 10% of subjects are generally classified as Fitzpatrick skin phototype class V30,31. The 
mechanistic explanation for these intriguing results needs to be further considered. Since skin fluorophore detec-
tion sensitivity highly depends on the efficiency of excitation light delivery, the effective launching of incident 
light to the desired skin layers is critical to ensure accurate measurement of skin fluorescence.
In a reflection-geometry system, the majority of incident light is directly reflected back by the surface of volar 
side of the forearm32. The reduced delivery of incident light in the desired tissue layers can produce poor detection 
sensitivity of skin fluorophore density. On the other hand, in the diffused transmission-geometry system, effective 
delivery of SAF excitation light owing to significant reduction of direct light reflection from skin surface as well 
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as anisotropic diffusion of photons can potentiate a better SAF measuring performance than systems involving 
reflection-geometry15. In addition to better excitation light delivery in transmission-geometry system, unlike 
the volar side of the forearm on which existing optical systems detect skin fluorescence, the secretion of dick-
kopf –related protein 1 (DKK1) in palmoplantar human skin suppresses melanocyte function and growth33. The 
melanocyte density in the 1st dorsal interossei is much less than that found on the volar side of the forearm. Thus, 
skin auto-fluorescence measurement in the 1st dorsal interossei muscle can be less affected by dermal chromo-
phore density. Overall, SAF detection with a transmission-geometry system in the palmoplantar sites potentiates 
a better SAF measuring performance than systems involving reflection-geometry.
The pathophysiological processes triggered AGE accumulation can affect a wide variety of human tissues and 
a substantial number of T2DM patients gradually develop multiple complications3,34. Thus, various types of med-
ical examination are highly necessary for the complete diagnosis of all of these complications. However, multiple 
examinations on patients without the corresponding complications are costly. Therefore, if one can diagnose the 
severity of diabetic complications beforehand, the time and cost of the overall testing can be reduced. Here, we 
found that skin auto-fluorescence measured in the 1st dorsal interossei muscle dramatically increased in patients 
with multiple microvascular complications, which suggests that skin auto-fluorescence can be a marker for the 
severity of diabetic complications.
Furthermore, the duration of abnormal glucose metabolism in patients with T2DM was significant longer 
in patients with multiple sustained diabetic complications. It is important to note that skin auto-fluorescence 
measured with a newly developed transmission-geometry optical system reflects the duration of T2DM. Because 
the duration of T2DM is a critical co-factor of the onset of diabetic complications in patients with T2DM35 
but unlike type 1 diabetes mellitus accurate assessment of T2DM duration often faces formidable obstacles. 
Non-invasive and reliable monitoring of T2DM duration holds a great potential for the setting of preemptive and 
patient-specific strategy against progressive diabetic complications.
In conclusion, palmoplantar SAF levels measured with a transmission-geometry optical system were tightly 
associated with the duration and the severity of microvascular complications in Korean patients with T2DM and 
the new modality of SAF detection could be used as regular monitoring methods for microvascular complications 
even in non-Caucasian subjects with dark skin type.
Methods
This study enrolled T2DM patients who were aged 20 years or older and did not have any disease or defects of the 
hand skin. Participants were treated with oral hypoglycemic agent or insulin at the Diabetes Center at Severance 
Hospital from May to July 2015. Informed consent was obtained from the participants, all of whom agreed to get 
their SAF measured. T2DM was diagnosed according to the International Classification of Diseases, 10th revi-
sion. Among 200 patients, 34 subjects without clinical parameters of HbA1c and glycated albumin within 1 week 
of SAF measurement were excluded. As a result, 166 patients were finally enrolled in this study. This study was 
carried out in accordance with the principles of the Declaration of Helsinki as revised in 2000. The study protocol 
was approved by the Ethics Committee of Yonsei University Health System, Severance Hospital (1-2012-0042 
and 1-2015-0014). In all subjects, physical examinations and plasma glucose measurements were performed. The 
microvascular complications including retinopathy, nephropathy, and neuropathy were diagnosed with conven-
tional screening methods. Briefly, urinary albumin/creatinine ratio (UACR) was calculated using results of urine 
microanalysis results (Hitachi 7180, Tokyo, Japan). The presence of diabetic nephropathy was defined as UACR 
of 30 mg/g or more. The presence of diabetic retinopathy was defined as the existence of either proliferative or 
non-proliferative retinal disease in dilated fundus examination by an ophthalmologist or a previous history of 
laser photocoagulation therapy. Nerve conducting velocity (NCV) was performed to confirm the presence of 
neuropathy. Abnormalities in sensory or motor neuronal velocity were defined as neuropathy. In addition, the 
presence of neuropathy was determined according to the existence of typical symptoms if diabetic neuropathy or 
history of medication for diabetic neuropathy. A group of subjects who were screened positive to any complica-
tion screening in general practice was defined as a complication group; otherwise defined as a non-complication 
group. The classification of hyperlipidemia and hypertension was made with previous diagnosis.
In each subject, reflected SAF on the volar side of the forearms and transmitted SAF in the 1st dorsal inter-
ossei muscle of the hand were measured with a currently developed multi-geometry optical system as described 
previously15. Briefly, in the reflection-geometry system, the volar side of the forearm was sequentially illumi-
nated with dual wavelength beams. The SAF and reference optical signals were collected and focused to a spec-
trometer (AvaSpec-2048-EDU-VIS Spectrometer; Avantes, Apeldoorn, Netherlands) for spectrum analysis. In 
the transmission-geometry system, the upper surface of the 1st dorsal interossei muscle of a hand was illumi-
nated by dual wavelength beams. The SAF emitted by the excitation beam and transmitted reference optical 
signals were collected by a multimode optical fiber located on the other side of muscle and focused to a spec-
trometer (AvaSpec-2048-EDU-VIS Spectrometer; Avantes) for spectrum analysis. The ratio of average SAF to 
non-fluorescent reference signals is used for SAF calibration, as previously reported12. The system was fully evalu-
ated and calibrated with customized fluorescent test samples (Labsphere, INC., North Sutton, NH) which have the 
same excitation (center wavelength: 370 nm) and emission (center wavelength: 440 nm) spectra to AGE-related 
fluorophores.
Among all T2DM subjects, a chi-square test was used for sex difference and a Mann-Whitney test was used 
for difference in DM duration between positive and negative subjects. All other statistical comparisons were 
made with an unpaired student’s t-test. One-way analysis of variance test was conducted to compare SAF val-
ues varying with the number of associated complications. Pearson’s and Spearman’s correlation coefficient were 
calculated for assessment of correlation between quantitative and qualitative variables, respectively. Univariate 
logistic regression analyses were performed in order to determine which variables among age, sex, DM duration, 
body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, high-density lipoprotein, 
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low-density lipoprotein and triglyceride, SAF-T determined the presence or development of microvascular dis-
ease. Factors with a P value less than 0.05 in the univariate model were introduced in to the multivariate logistic 
regression to estimate the odds ratio and 95% confidence interval. VIF was used to check multicollinearity of var-
iables. ROC curves were plotted to evaluate the diabetic complication screen performance of a newly developed 
transmission-geometry SAF measuring system. The optimal cutoff values for detecting a diabetic microvascular 
complication were identified using the maximum of the Youden index.
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